Matthew Taylor
Stock Analyst at Jefferies
(2.70)
# 2,146
Out of 5,036 analysts
179
Total ratings
61.11%
Success rate
11.24%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SI Shoulder Innovations | Initiates: Buy | $19 | $12.47 | +52.37% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $128.35 | +12.97% | 17 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $15.98 | -6.13% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $76.79 | +34.13% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $78.00 | -10.26% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $334.42 | -33.32% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $96.55 | -21.28% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $1.98 | +6,213.13% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $149.90 | -19.28% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $3.67 | +281.47% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $15.46 | +191.07% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $10 | $6.80 | +47.06% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $16.22 | +226.76% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $11.71 | +104.95% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $390.20 | -11.58% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $106.28 | +22.32% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $253.28 | -9.19% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $15.56 | +28.53% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $49.02 | +73.40% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $63.23 | +18.62% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $270.02 | -9.27% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $23.33 | +165.75% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $134.07 | +56.63% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $15.76 | -23.86% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $71.36 | +75.17% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $104.86 | -52.32% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $540.50 | -61.15% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $54.83 | +75.09% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.13 | +228.64% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $189.85 | +40.11% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $12.13 | +31.90% | 2 | Jul 19, 2017 |
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $12.47
Upside: +52.37%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $128.35
Upside: +12.97%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $15.98
Upside: -6.13%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $76.79
Upside: +34.13%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $78.00
Upside: -10.26%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $334.42
Upside: -33.32%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $96.55
Upside: -21.28%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $1.98
Upside: +6,213.13%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $149.90
Upside: -19.28%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $3.67
Upside: +281.47%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $15.46
Upside: +191.07%
Jul 19, 2023
Initiates: Underperform
Price Target: $10
Current: $6.80
Upside: +47.06%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $16.22
Upside: +226.76%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $11.71
Upside: +104.95%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $390.20
Upside: -11.58%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $106.28
Upside: +22.32%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $253.28
Upside: -9.19%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $15.56
Upside: +28.53%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $49.02
Upside: +73.40%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $63.23
Upside: +18.62%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $270.02
Upside: -9.27%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $23.33
Upside: +165.75%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $134.07
Upside: +56.63%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $15.76
Upside: -23.86%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $71.36
Upside: +75.17%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $104.86
Upside: -52.32%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $540.50
Upside: -61.15%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $54.83
Upside: +75.09%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.13
Upside: +228.64%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $189.85
Upside: +40.11%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $12.13
Upside: +31.90%